AI-enabled symptom checker Infermedica has raised $10.25 million in Series A funding.
Infermedica says the new funds will be used for research and development to further enhance patient triage and symptom checking features as well as clinical decision support analysis – including intake collection, differential diagnostics, and lab test interpretation.
The funds will also enable the company’s expanding operations in Germany and the US, where Infermedica currently has one office.
The funding round was led by the European Bank for Reconstruction and Development (EBRD) and digital health fund Heal Capital, with participation from existing investors Karma Ventures, Inovo Venture Partners, and Dreamit Ventures.
The company operates as a business-to-business model and helps insurance, telemedicine companies, and health systems increase efficiency through fast, digital symptom-checks.
The Infermedica platform’s available interfaces include Symptom Checker, a chatbot and voice assistant that provides fast digital symptom checking and analysis, suggesting a list of the most likely conditions. Call Centre Triage, a solution that aids telemedicine personnel to pre-diagnose patients and understands condition severity so they can provide relevant healthcare instructions while avoiding unnecessary urgent care visits. And Infermedica API, an API that can be integrated directly onto websites, apps, or telehealth systems.
The app is currently being used by nearly 60 business-to-business partners across 30 countries, including Microsoft, Allianz, Global Excel, Sana Kliniken, and Médis. And the app has offered more than 6 million health checks, according to the company.
According to New England Healthcare Institute, 25% of cases can be self-treated or treated through teleconsultation, and $38 billion can be saved per year when patients are led to proper care (in the US only).
Infermedica, founded in 2012, has raised $15 million to date, according to Mercom data. Investors include Estonian investor Karma Ventures led the round with participation from Dreamit Ventures, Inovo Venture Partners, and Müller Medien.
Image credit: Infermedica
